Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Major Shareholder Purchases $7,474,720.00 in Stock

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) major shareholder Jolla Pharmaceutical Co La purchased 3,737,360 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was purchased at an average price of $2.00 per share, with a total value of $7,474,720.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Jolla Pharmaceutical Co La also recently made the following trade(s):

  • On Friday, June 19th, Jolla Pharmaceutical Co La purchased 234,698 shares of Tetraphase Pharmaceuticals stock. The stock was purchased at an average price of $2.62 per share, with a total value of $614,908.76.

Shares of NASDAQ TTPH opened at $2.20 on Friday. The company has a quick ratio of 3.56, a current ratio of 3.66 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average price is $2.47 and its two-hundred day moving average price is $2.02. Tetraphase Pharmaceuticals Inc has a 52-week low of $0.56 and a 52-week high of $8.60. The stock has a market capitalization of $15.97 million, a P/E ratio of -0.12 and a beta of 2.33.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.63) by $0.32. Tetraphase Pharmaceuticals had a negative net margin of 798.18% and a negative return on equity of 210.86%. The firm had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $2.45 million. As a group, equities research analysts expect that Tetraphase Pharmaceuticals Inc will post -3.95 earnings per share for the current year.

A number of equities analysts recently commented on TTPH shares. Gabelli upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 7th. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Finally, G.Research downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 26th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. Tetraphase Pharmaceuticals has an average rating of “Hold” and an average price target of $21.25.

A number of hedge funds and other institutional investors have recently modified their holdings of TTPH. Bank of New York Mellon Corp bought a new position in Tetraphase Pharmaceuticals in the first quarter worth about $36,000. Geode Capital Management LLC raised its holdings in shares of Tetraphase Pharmaceuticals by 52.0% during the fourth quarter. Geode Capital Management LLC now owns 30,826 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 10,541 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Tetraphase Pharmaceuticals by 20.3% during the first quarter. BlackRock Inc. now owns 69,799 shares of the biopharmaceutical company’s stock valued at $89,000 after buying an additional 11,757 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Tetraphase Pharmaceuticals by 38.2% during the fourth quarter. Renaissance Technologies LLC now owns 224,940 shares of the biopharmaceutical company’s stock valued at $632,000 after buying an additional 62,125 shares during the last quarter. Finally, Sabby Management LLC bought a new stake in shares of Tetraphase Pharmaceuticals during the first quarter valued at approximately $854,000. 42.29% of the stock is currently owned by hedge funds and other institutional investors.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: How Buying a Call Option Works

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.